Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 0: clinchem.2007.098368v1, 2008; 10.1373/clinchem.2007.098368
This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2007.098368v1
54/3/534    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vermeulen, N.
Right arrow Articles by Bossuyt, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vermeulen, N.
Right arrow Articles by Bossuyt, X.

Received on October 2, 2007
Accepted on December 27, 2007

Clinical Immunology

Anti–{alpha}-enolase Antibodies in Patients with Inflammatory Bowel Disease

Nathalie Vermeulen 1, Ingrid Arijs 1, Sofie Joossens 1, Severine Vermeire 1, Stefan Clerens 2, Karolien Van den Bergh 3, Georges Michiels 3, Lutgarde Arckens 2, Frans Schuit 4, Leentje Van Lommel 4, Paul Rutgeerts 1, Xavier Bossuyt 3*

1 Department of Internal Medicine, University Hospital Leuven, Leuven, Belgium
2 Laboratory of Neuroplasticity and Neuroproteomics, Katholieke Universiteit Leuven, Leuven, Belgium
3 Department of Laboratory Medicine, University Hospital Leuven, Leuven, Belgium
4 Department of Molecular Celbiology, University Hospital Leuven, Leuven, Belgium

* To whom correspondence should be addressed. E-mail: Xavier.Bossuyt{at}uz.kuleuven.ac.be.

BACKGROUND: Patients with inflammatory bowel disease (IBD) carry autoantibodies such as perinuclear antineutrophil cytoplasmic antibodies (pANCA). {alpha}-Enolase has been proposed as a target antigen in IBD. We evaluated the prevalence and diagnostic value of anti–{alpha}-enolase antibodies in IBD and related disorders.

METHODS: We used a classic proteomic approach with extracts from granulocytes and pANCA-positive ulcerative colitis (UC) sera to confirm {alpha}-enolase as a target antigen. By means of Western blot analysis, we screened a cohort of 525 subjects for the presence of anti–{alpha}-enolase antibodies. We performed GeneArray experiments on RNA extracted from colonic mucosal biopsies from 35 IBD and 6 control patients.

RESULTS: We detected anti–{alpha}-enolase antibodies 49.0% of patients with UC, 50.0% of patients with Crohn's disease, 30.5% of patients with primary sclerosing cholangitis, 37.8% of patients with autoimmune hepatitis, 34.0% of patients with ANCA-positive vasculitis, 31.0% of non-IBD gastrointestinal controls, and 8.5% of healthy controls. Gene array experiments showed a significant upregulation of {alpha}-enolase mRNA in colonic mucosal biopsies from patients with IBD, but not from controls. There was no association between the presence of pANCA and anti–{alpha}-enolase antibodies. Preabsorption with {alpha}-enolase did not eliminate the pANCA pattern on indirect immunofluorescence.

CONCLUSIONS: Anti–{alpha}-enolase antibodies are present in a substantial proportion of patients with IBD, patients with various inflammatory/autoimmune disorders, and non-IBD gastrointestinal controls. Therefore, anti–{alpha}-enolase antibodies are of limited diagnostic value for the diagnosis of IBD.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the American Association for Clinical Chemistry.